By blocking this process, DNMTi, when combined with the PD-1 blockade, rejuvenates CD8+ T cells, leading to a synergized anti-tumor effect by preventing CD8+ T cell exhaustion [176]. This evidence concerns the gene CD8A and neoplasm.